Immutep Ltd · ASX:IMM

Immutep — Investor Presentation (December 2022)

33 slides from Immutep's investor presentation, December 2022

  1. Slide 1: Unlocking the power of the adaptive & innate immune system with LAG-3 therapeutics

    Unlocking the power of the adaptive & innate immune system with LAG-3 therapeutics. I Corporate Presentation – December 2022 (ASX: IMM, NASDAQ: IMMP)

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarificati

  3. Slide 3: Immutep Overview

    Immutep Overview Pioneering LAG-3 Therapeutics Immutep is a a clinical-stage biotechnology company developing novel LAG-3 immunotherapies that address significant market opportunities in oncology and autoimmune disease. Compelling Clinical Data Lead candidate eftilagimod alpha (efti) has shown compe

  4. Slide 4: Immutep LAG-3 Pipeline

    Immutep LAG-3 Pipeline Program Indication Preclinical Phase I Phase II Late Stage* Commercial Rights 1st Line HNSCC TACTI-003 | Efti+Pembrolizumab a 1st Line NSCLC, 2nd Line HNSCC, TACTI-002 | Efti+Pembrolizumab a PD-X Refractory 2nd Line NSCLC Metastatic Melanoma TACTI-mel | Efti+Pembrolizumab a Re

  5. Slide 5: LAG-3: A Validated Immune Checkpoint

    LAG-3: A Validated Immune Checkpoint Regulatory approval of immunotherapies (IO) targeting CTLA-4, PD-1, and now LAG-3* immune checkpoints (IC) highlight the immune system’s powerful role in fighting cancer. Unfortunately, up to 80% of patients do not respond to IC monotherapy, driving a need for ne

  6. Slide 6: Efti: First-in-Class Soluble LAG-3 Key to Unlock Immune System

    Efti: First-in-Class Soluble LAG-3 Key to Unlock Immune System Efti acts as a key to unlock broad immune system activation to fight cancer Eftilagimod alpha (Efti) APC activation with Efti Significant increase in anti-tumor immune cells & serum biomarkers LAG-3 Efti APC Human IgG1 MHC II Dendritic C

  7. Slide 7: Synergy with Chemotherapy & IO Checkpoint Inhibitors

    Synergy with Chemotherapy & IO Checkpoint Inhibitors Chemotherapy releases cancer Activated APCs via efti acquire cancer Cytotoxic CD8+ T cells & other cells Efti enhances anti-PD-(L)1 therapies’ antigens via cancer cell death antigens & present to cytotoxic T cells generated from efti infiltrate tu

  8. Slide 8: Substantial Commercial Opportunity

    Substantial Commercial Opportunity Efti has doubled overall response rates of anti-PD-1 therapy (KEYTRUDA®), and also has shown encouraging signals of efficacy with anti-PD-L1 therapy (BAVENCIO®) and standard-of-care (SOC) chemotherapy. Its promise to safely improve outcomes across the entire PD-L1

  9. Slide 9: Pipeline in a Product

    Pipeline in a Product Efti Clinical Trials Confirm Broad Potential Preclinical Phase I Phase II Late Stage* 1st Line HNSCC Efti + Pembrolizumab a 1st Line NSCLC, 2nd Line HNSCC, Efti + Pembrolizumab a PD-X Refractory 2nd Line NSCLC IO-IO Chemo-IO Metastatic Melanoma Efti + Pembrolizumab a Combinatio

  10. Slide 10: TACTI-002 Phase II Trial: Efti + Pembrolizumab in 1L NSCLC

    TACTI-002 Phase II Trial: Efti + Pembrolizumab Combination in 1st Line Non-Small Cell Lung Cancer (1L NSCLC) *Dr. Wade Iams presenting data from TACTI-002/KEYNOTE-798 *Dr. Enriqueta Felip presenting data from TACTI-002/KEYNOTE-798 in10 Late Breaking Abstract Oral Presentation at SITC 2022 in Oral Pr

  11. Slide 11: Treatment Options in 1L NSCLC Limited by Durability & Tolerability

    Treatment Options in 1L NSCLC Limited by Durability & Tolerability 1L NSCLC Epidemiology1,2 – 1.87 million NSCLC diagnoses per annum – NSCLC is the highest cause of death among all cancers – Immutep is focused on improving clinical responses for the 1.3 million patients that develop metastatic disea

  12. Slide 12: Phase II Trial Evaluating Efti + Pembrolizumab in 1L NSCLC

    Phase II Trial Evaluating Efti + Pembrolizumab in 1L NSCLC TACTI-002/KEYNOTE-798: 1st Line Non-Small Cell Lung Cancer (Part A) TACTI-002: Two ACTive Immunotherapeutics in NSCLC & HNSCC Baseline characteristics for PD-L1 All Comer Trial Part A (N=114) Age, median (range), years 67 (44-85) Sex, n (%)

  13. Slide 13: Compelling Clinical Results; Primary Objective Achieved

    Compelling Clinical Results; Primary Objective Achieved TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) TACTI-002 Phase II (1L NSCLC) Clinical Data and Key Takeaways SITC 2022 Late-Breaking Abstract Oral Presentation • 40.4% overall response rate (ORR); primary objective achieved • Robust interim median Du

  14. Slide 14: Deep and Durable Responses

    Deep and Durable Responses TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) 2, 3 Tumor Burden Reduced in Majority of Patients Interim Median Duration of Response (DoR) 100 100 DoR by iRECIST (N=40) (%) (%) 75 90 80 Events, n (%) 10 (25.0) Response Best % change from baseline 50 70 Median, months [95% CI]4 2

  15. Slide 15: Promising Progression Free Survival (PFS)

    Promising Progression Free Survival (PFS) TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) PFS1 – PD-L1 all comer (ITT) PFS1 by PD-L1 status 100 PFS1 (N=114) 100 PD-L1 TPS (central) Median, months [95% CI] Events, n (%) (%) (%) (%) (%) 90 Events, n (%) 73 (64.0) 90 ≥50% (N=20) 16.7 [4.0-16.8] 10 (50.0) Surv

  16. Slide 16: Benchmarking against Pembrolizumab Monotherapy

    Benchmarking against Pembrolizumab Monotherapy: Strong ORR/PFS Across Entire PD-L1 Spectrum vs Pembro Mono TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) Overall Response Rate* (ORR) Median Progression Free Survival# (PFS) (with 95% confidence interval) (by PD-L1 TPS Score) Median Progression Pembro mono

  17. Slide 17: Benchmarking against Pembrolizumab Monotherapy and Pembrolizumab-Chemotherapy Combination in 1L NSCLC

    Benchmarking against Pembrolizumab Monotherapy and Pembrolizumab-Chemotherapy Combination in 1L NSCLC TACTI-002/KEYNOTE-798: 1L NSCLC (Part A) Additional ORR PFS DoR Toxicity Efti + pembro High High High* No Pembro mono Low Low High* No Pembro + chemo High High Low Yes *Note 34% patients in TACTI-00

  18. Slide 18: Additional Clinical Studies with Efti and Anti-PD-(L)1, Chemotherapy or Triple Combination

    Additional Clinical Studies with Efti and Anti-PD-(L)1, Chemotherapy or Triple Combination

  19. Slide 19: Focusing Efti on Indications with High Unmet Needs

    Focusing Efti on Indications with High Unmet Needs Efti Late Stage Clinical Development Head and Neck Squamous Cell Carcinoma (HNSCC) – There are ~900K cases and >400K deaths per annum in HNSCC1 – Pembrolizumab with chemotherapy is approved for 1st line HNSCC and pembrolizumab monotherapy is approve

  20. Slide 20: 2L HNSCC: Robust ORR/CR with Long-Lasting Efficacy

    2L HNSCC: Robust ORR/CR with Long-Lasting Efficacy TACTI-002/KEYNOTE-798: 2nd Line Head & Neck Squamous Cell Carcinoma (Part C) TACTI-002 Part C: 2nd Line Head & Neck Squamous Cell Carcinoma Responses at all PD-L1 levels including 5 iCRs Efti + Keytruda Keytruda Combination* Monotherapy# Best % chan

  21. Slide 21: TACTI-003 Targeting 1L HNSCC with Fast Track Designation

    TACTI-003 Targeting 1L HNSCC with Fast Track Designation TACTI-003: Phase IIb in 1st Line Head and Neck Squamous Cell Carcinoma (HNSCC) TACTI-003 - Randomized Phase IIb Trial in 1L HNSCC Patients Higher ORR & mOS from pembro + doublet chemo in 1L HNSCC comes with additional toxicity and at the expen

  22. Slide 22: AIPAC Phase IIb: Driving OS Improvement with Superior QoL

    AIPAC Phase IIb: Driving OS Improvement with Superior QoL AIPAC: Active Immunotherapy PAClitaxel in HER2–/ HR+ metastatic breast cancer Phase IIb Trial Statistically-Significant Increase of Statistically-Significant Correlation: Cytotoxic CD8+ T Cell Count OS & Cytotoxic CD8+ T cell count AIPAC: Mul

  23. Slide 23: Treating PD-X Refractory Patients in 2L NSCLC

    Treating PD-X Refractory Patients in 2L NSCLC TACTI-002/KEYNOTE-798: 2nd Line NSCLC, PD-X Refractory (Part B) ORR, PFS and OS for ITT and PD-L1 subgroups Best overall response, ITT TACTI-002 Part B: 2nd Line NSCLC, PD-X Refractory PD-L1 TPS ITT (N=36) <1% (N=13) 1-49% (N=14) >50% (N=6) Tumor respons

  24. Slide 24: Efti + Anti-PD-L1 (Avelumab) in Advanced Solid Tumors

    Efti + Anti-PD-L1 (Avelumab) in Advanced Solid Tumors INSIGHT-004: Phase I in Various Advanced Solid Tumors & INSIGHT-005: Phase I in Metastatic Urothelial Cancer INSIGHT-004 - Phase I dose escalation study in INSIGHT-005 - Phase I study in metastatic advanced solid tumors urothelial cancer • Efti i

  25. Slide 25: IO + IO + Chemo Combination Trial (INSIGHT-003)

    IO + IO + Chemo Combination Trial (INSIGHT-003) INSIGHT-003: Phase I in Solid Tumors Focusing on NSCLC Adenocarcinomas INSIGHT-003 - Third arm (Stratum C) of ongoing investigator- Initial Efficacy initiated study focusing on NSCLC adenocarcinomas Tumor Response according to RECIST 1.1 (N=11) Complet

  26. Slide 26: IMP761: LAG-3 Therapeutic for Autoimmune Diseases

    IMP761: LAG-3 Therapeutic for Autoimmune Diseases

  27. Slide 27: LAG-3: A Key Target in Autoimmune Diseases

    LAG-3: A Key Target in Autoimmune Diseases Present Approaches Fight the Symptoms of Autoimmune Diseases Treating general inflammation: Corticoids, methotrexate, anti-TNF-α, -IL-6, -IL-17, -IL-23 mAbs Future Approaches Target the Causes of Autoimmune Disease Treating the disease process: Targeting au

  28. Slide 28: IMP761: Broad Potential Targeting Auto-Reactive Memory T Cells

    IMP761: Broad Potential Targeting Auto-Reactive Memory T Cells Deficiency in LAG3 Pathways Linked to Development of Autoimmune Diseases (AI) IMP761 LAG-3 LAG-3 IMP761, a first-in-class LAG-3–specific agonist antibody acting upstream on activated T cells, A LAG -3–Specific Agonist Antibody for the Tr

  29. Slide 29: IMP761 Inhibits Inflammatory T Cell Infiltration In Vivo

    IMP761 Inhibits Inflammatory T cell Infiltration In Vivo IMP761 significantly inhibits T cell infiltration of an antigen-specific intradermal reaction in vivo in an Ag-specific delayed-type hypersensitivity (DTH) model in non-human primate study Inflammatory T cell infiltration test 1 vs test 2 Perc

  30. Slide 30: Board and Management

    Board and Management Dr Russel Howard Pete Meyers Lucy Turnbull, AO Marc Voigt Prof. Frédéric Triebel, MD Ph.D. Deanne Miller Non-Executive Chairman Deputy Chairman Non-Executive Director Executive Director & CEO Executive Director, CSO & CMO COO, General Counsel Dr Howard has over 45 years Mr Meyer

  31. Slide 31: Milestones

    Milestones 2022 2023 • Industry Conference Presentations: • TACTI-003 updates and top line readout  ASCO - Oral Presentation (TACTI-002; 1L NSCLC) • TACTI-002 data updates  ELCC & WCLC - PD-X refractory data (TACTI-002; 2L NSCLC ) • INSIGHT-003 updates and readout  SITC - Late-Breaking Abstract &

  32. Slide 32: Summary

    Summary • Pioneering LAG-3 portfolio in oncology & autoimmune diseases with three clinical & two pre-clinical assets • First-in-class positioning with eftilagimod alpha (efti) that has strong IP protection • Multiple big pharma partnerships & collaborations with efti, while retaining full global rig

  33. Slide 33: Thank You

    : =) Iimmutep Thank You

Immutep — Investor Presentation (December 2022) on 6ix